Raised hopes for prostate cancer sufferers Times Online, UK - When hormonal treatment for prostatic cancer was started, doctors surgically castrated their patients or gave them large doses of female hormone. ...
For the first time, rate of new cases in both men and women is ... Houston Chronicle, United States - Nov 25, 2008 Fewer men and women are being screened for prostate and breast cancer, they noted, which can mean fewer tumors get identified. And as the population ages ...
Prostate Cancer Treatment: The Options HealthNews, CA - Nov 20, 2008 These results indicate that patients need extensive consultations prior to deciding whether they should have surgery, radiation, or hormone therapy versus ...
Elderly may fare worse on prostate cancer drugs Chicago Daily Herald, IL - Nov 16, 2008 AP A prostate cancer study that could change how doctors treat some patients found that widely used hormone-blocking drugs did not improve survival chances ...
Avastin? May have Activity in Hormone-refractory Prostate Cancer Cancer Consultants, ID - Nov 7, 2008 Researchers from Italy have reported that Avastin? (bevacizumab) plus docetaxel (Taxotere?) may have activity in patients with hormone-refractory prostate...
Diatos Launches Two International Multi-center Phase II Clinical ... PharmaLive.com (press release), PA - Aug 5, 2008 DTS-201 Prostate Cancer Phase II Trial The first patient has been treated in the clinical Phase II study of DTS-201 for hormone refractory prostate cancer ...
New prostate drug Abiraterone on clinical trials Irish Times, Ireland - Jul 28, 2008 This trial confirms that castration-resistant prostate cancer commonly remains hormone driven. Abiraterone uses a different method from conventional ...
Immunotherapy of Hormone-Refractory Prostate Cancer With Antigen-Loaded Dendritic Cells - EJ Small, P Fratesi, DM Reese, G Strang, R Laus, … - Journal of Clinical Oncology, 2000 - jcojournal.org ... manipulations, 3 all patients ultimately develop hormone-refractory prostate cancer
(HRPC). ... to induce tumor-specific immunity in the patient and is ...
Men with prostate cancer taking long-term hormone drugs could be nearly twice as likely to survive the disease as patients treated with radiotherapy alone, say researchers.
A study shows drug therapy for three years almost doubled the survival rate after five years in men with advanced prostate cancer, who normally have a poor rate of recovery.
Cases of the disease in the UK are rapidly increasing --partly because it is being picked up earlier in younger men - with around 21,000 men diagnosed each year.
Hormone therapy has already been used on women to cut breast cancer recurrence rates.
Many British oncologists prescribe hormone therapy to men in the advanced stages of the disease, in addition to radiotherapy, because it improves their quality of life.
But there had been little evidence that it helps them live longer. The trial, co-ordinated by researchers at University Hospital, Grenoble, in France, investigated the benefit of antiandrogen drugs which block production of the male hormone testosterone which can accelerate the growth of the cancer.
Altogether 415 patients were randomly assigned radiotherapy or radiotherapy plus hormone suppression. Those given the combined therapy had a substantially increased fiveyear disease-free survival rate, at 74 per cent, compared with 40 per cent of patients given radiotherapy alone, says a report in The Lancet today.
Professor Jonathan Waxman, professor of Oncology at Hammersmith Hospital, London, and chairman of the Prostate Cancer Charity, said: 'The study is important because it shows long-term hormone therapy has survival benefits.'
